Cooke, S. L. and Brenton, J. D. (2011) Evolution of platinum resistance in high-grade serous ovarian cancer. Lancet Oncology, 12(12), pp. 1169-1174. (doi: 10.1016/S1470-2045(11)70123-1) (PMID:21742554)
Full text not currently available from Enlighten.
Abstract
High-grade serous ovarian cancers account for most ovarian-cancer mortality. Although this disease initially responds well to platinum-based chemotherapy, relapse and progression to chemotherapy resistance are frequently seen. Time to relapse after first-line therapy is a predictor of response to secondary platinum treatment: more than 12 months is associated with high chance of a secondary response, whereas relapses within 6 months generally indicate platinum resistance. In this Personal View we discuss whether patterns of response, relapse, and the development of drug resistance in high-grade serous ovarian cancers are related to distinct underlying molecular and cellular biological characteristics. In particular, we propose that rapid relapse with platinum-resistant disease is due to minor subpopulations of intrinsically resistant cancer cells at presentation.
| Item Type: | Articles |
|---|---|
| Status: | Published |
| Refereed: | Yes |
| Glasgow Author(s) Enlighten ID: | Cooke, Dr Susie |
| Authors: | Cooke, S. L., and Brenton, J. D. |
| College/School: | College of Medical Veterinary and Life Sciences > School of Cancer Sciences |
| Journal Name: | Lancet Oncology |
| Publisher: | Elsevier |
| ISSN: | 1470-2045 |
| ISSN (Online): | 1474-5488 |
| Published Online: | 11 July 2011 |
University Staff: Request a correction | Enlighten Editors: Update this record
Altmetric
Altmetric